Investment Summary |
|
---|---|
Date | 2013-01-07 |
Target | Ralink Technology |
Sector | Technology Hardware |
Sellers(s) | H&Q Asia Pacific |
Deal Type | Merger |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Private Equity Firm |
---|---|
Founded | 1985 |
PE ASSETS | 3.4B USD |
Size | Mega |
Type | Sector Agnostic |
H and Q Asia Pacific (H&QAP) is a private equity firm focused on later-stage control investments and earlier-stage venture capital investments across the Pacific Rim. Areas of interest include technology, technology manufacturing, consumer brands, and financial services. The Group was originally formed in 1985 as a division of US investment bank Hambrecht & Quist and is now an independent organization. H&Q Asia Pacific has offices in Palo Alto, California; Hong Kong; Manila; Shanghai; Taipei; and Tokyo.
DEAL STATS | # |
---|---|
Overall | 15 of 20 |
Sector (Technology Hardware) | 3 of 3 |
Type (Merger) | 2 of 2 |
Country (Taiwan) | 3 of 4 |
Year (2013) | 1 of 1 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2012-10-05 |
Primax Electronics
Taipei, Taiwan Primax Electronics manufactures and sells computer peripherals and non-computer peripherals in Taiwan and internationally. The company offers gaming/PC peripherals, lighting solutions, wireless charging solutions, docking stations, smart access solutions, and digital door locks/door bells; in-car connected cameras, intelligent gateways, smart sensors and trackers, advanced driver assistance systems camera modules, smartphone camera modules, home IoT cameras, surveillance cameras, multi-function printers, and content creation devices. Primax Electronics was founded in 1984 and is based in Taipei, Taiwan. |
Sell | - |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2013-12-12 |
Senhwa Biosciences
New Taipei City, Taiwan Senhwa Biosciences is a drug development company, engages in the development of new drugs and special pharmaceutical ingredients. The company develops CX-5461, a phase I, open-label, dose escalation, safety, pharmacokinetic, and pharmacodynamics study of intravenously administered CX-5461 in patients with advanced hematologic malignancies; and CX-5461 CA, which is in phase I clinical trials in patients with solid tumors and BRCA2 and/or PALB2 mutation. Senhwa Biosciences was founded in 2012 and is based in New Taipei City, Taiwan. |
Buy | - |